143 related articles for article (PubMed ID: 21094428)
1. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
Biedenbach DJ; Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2010 Dec; 68(4):459-67. PubMed ID: 21094428
[TBL] [Abstract][Full Text] [Related]
2. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
3. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
4. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
5. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
6. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
7. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).
Mendes RE; Hogan PA; Streit JM; Jones RN; Flamm RK
J Antimicrob Chemother; 2014 Jun; 69(6):1582-8. PubMed ID: 24468866
[TBL] [Abstract][Full Text] [Related]
8. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
[TBL] [Abstract][Full Text] [Related]
9. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of linezolid resistance in Germany, 2001-2002.
Brauers J; Kresken M; Hafner D; Shah PM;
Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
[TBL] [Abstract][Full Text] [Related]
11. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
[TBL] [Abstract][Full Text] [Related]
12. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
13. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
[TBL] [Abstract][Full Text] [Related]
14. Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries.
Ross JE; Farrell DJ; Mendes RE; Sader HS; Jones RN
J Chemother; 2011 Apr; 23(2):71-6. PubMed ID: 21571621
[TBL] [Abstract][Full Text] [Related]
15. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
[TBL] [Abstract][Full Text] [Related]
16. United States resistance surveillance results for linezolid (LEADER Program for 2007).
Jones RN; Ross JE; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
[TBL] [Abstract][Full Text] [Related]
17. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
[TBL] [Abstract][Full Text] [Related]
18. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Antimicrob Agents Chemother; 2011 Aug; 55(8):3684-90. PubMed ID: 21670176
[TBL] [Abstract][Full Text] [Related]
19. Experience with linezolid therapy in children with osteoarticular infections.
Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.
Yoon EJ; Jo YW; Choi SH; Lee TH; Rhee JK; Yoo M; Shim MJ; Choi EC
Antimicrob Agents Chemother; 2005 Jun; 49(6):2498-500. PubMed ID: 15917554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
